ALK tyrosine kinase ALK TK is an important target in the development of anticancer drugs. In
the present work, we have performed a QSAR analysis on a dataset of 224 molecules in …

Simple Summary Targeted therapy has become essential in the treatment of non-small cell
lung cancer (NSCLC). There are currently no guidelines for older patients who are frailer …

Background: Somatic genomic testing is recommended by numerous expert guidelines to
inform targeted therapy treatment for patients with advanced non-squamous non-small cell …

The echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase
(ALK) fusion gene occurs in approximately 5% of non-small-cell lung cancers (NSCLCs) …

Background Anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non–small cell lung
cancer (NSCLC) represents a rare subset of lung cancer, with specific presentation, and …

Lung cancer classification has been radically transformed in recent years as genomic
profiling has identified multiple novel therapeutic targets including MET exon 14 (METex14) …

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounting for
almost 80%–85% of all lung cancer cases. Unfortunately, more than half of the patients will …

The concept of liquid biopsy as an analysis tool for non-solid tissue carried out for the
purpose of providing information about solid tumors was introduced approximately 20 years …

Introduction Amivantamab is a monoclonal bispecific anti-EGFR-MET antibody that is the
first targeted therapy to be approved for non-small cell lung cancer (NSCLC) patients …

According to the authors and editors, this report contains the most justified principles of
diagnostic and therapeutic procedures prepared, considering the scientific value of …